[Japon] Japan biotech startup pushes for mRNA shot suited for mass production
Wataru Akahata, CEO of VLP Therapeutics Japan LLC, thinks he can help provide a solution to the challenge of securing COVID-19 vaccines for billions of people — the development of a second-generation messenger RNA (mRNA) vaccine that requires only a fraction of the dosage of those currently available.